Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07251608 · ClinicalTrials.gov registry record · Phase 1
Randomized, Open-label, Safety Study of Subcutaneous and Intramuscular Injections of Niagen® Plus
A Phase 1 study of Healthy Volunteer and Fatigue, sponsored by ChromaDex.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT07251608 is a Phase 1 study of Healthy Volunteer and Fatigue that is actively recruiting participants, run by ChromaDex. The registered enrollment target is 40 participants, below the 201-participant average among 112 other Healthy Volunteer trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07251608, a Phase 1 study of Healthy Volunteer and Fatigue, is actively recruiting participants, sponsored by ChromaDex.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to learn about the safety of Niagen®Plus, an injectable form of nicotinamide riboside (NR), and to see how it affects levels of NAD+ in the blood. Niagen®Plus will be given either by subcutaneous (under the skin) or intramuscular (into the muscle) injection at two dose levels (50 mg or 100 mg). The main questions this study aims to answer are: Is Niagen®Plus safe and well-tolerated when given by injection several times over 100 days? How do NAD+ levels in blood change after repeated doses of Niagen®Plus? What are participants' and clinicians' experiences with the injections? Researchers will also look at changes in fatigue, sleep, quality of life, inflammation markers, mitochondrial efficiency, and perceived skin appearance. Participants will: Receive three injections in clinic on Days 1-3, followed by a Day 10 follow-up visit Self-inject Niagen®Plus at home three times per week from Days 10-100 Return to the clinic on Days 40 and 100 for safety and laboratory testing Complete short surveys about fatigue, sleep, and overall well-being throughout the study The study will include 40 generally healthy adults and will last about 100 days per participant.
Conditions Studied
Interventions
- DRUG Niagen®Plus
Study Locations (1)
Florida
- BTT Medical Institute Aventura North - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-10-01 |
| Est. Completion | 2026-02-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07251608
The ClinicalTrials.gov registry entry for NCT07251608 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 201-participant average among 112 other Healthy Volunteer trials with a reported enrollment target (80% lower). The listed sponsor is ChromaDex, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Healthy Volunteer appearing as the primary indexed condition, and to 1 intervention - of which Niagen®Plus is the first listed.
NCT07251608 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT07251608 about?
NCT07251608 is a clinical study titled "Randomized, Open-label, Safety Study of Subcutaneous and Intramuscular Injections of Niagen® Plus". The goal of this study is to learn about the safety of Niagen®Plus, an injectable form of nicotinamide riboside (NR), and to see how it affects levels of NAD+ in the blood. Niagen®Plus will be given either by subcutaneous (under the skin) or intramuscular (into the muscle) injection at two dose leve...
What is the current status of trial NCT07251608?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2025-10-01. Estimated completion is 2026-02-15.
What conditions does trial NCT07251608 study?
This clinical trial studies the following conditions: Healthy Volunteer, Fatigue.
What interventions are being tested in trial NCT07251608?
The interventions under investigation include: Niagen®Plus (DRUG).
Who is sponsoring clinical trial NCT07251608?
This trial is sponsored by ChromaDex, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07251608 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Volunteer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Healthy Volunteer Study
RECRUITING · Phase 1
-
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
RECRUITING · Phase 1
-
Role of Metal Ion Transporter ZIP8 in Alcohol-Related Behaviors
RECRUITING · Phase 1
-
A First-in-Human Single and Multiple Ascending Dose Study of MT-201
RECRUITING · Phase 1
-
A Study to Assess the Adverse Events and How Oral Emraclidine Moves Through the Body of Healthy Elderly Adult Participants
RECRUITING · Phase 1
-
A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian Participants
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.